Novo Nordisk says it’s cutting 9,000 workers amid increased competition for its obesity drug Wegovy

Novo Nordisk, a Danish pharmaceutical company known for its weight-loss drug Wegovy, announced on Wednesday that it will be cutting 9,000 jobs, which accounts for 11% of its workforce. This decision comes as the company faces increased competition in the market for obesity medications.

The company stated that approximately 5,000 of the job cuts will be in Denmark, with the remaining 4,000 positions being eliminated elsewhere. Novo Nordisk, which also produces Ozempic, a diabetes drug that can lead to weight loss, aims to save $1.25 billion by the end of 2026 through this streamlining effort. The savings will be redirected towards diabetes and obesity research and development.

The need for these job cuts is attributed to the evolving dynamics of the obesity market, which has become more competitive and consumer-driven, resulting in slower growth for Novo Nordisk. President and CEO Mike Doustdar emphasized the importance of adapting to these changes by fostering a more performance-based culture, optimizing resource allocation, and investing strategically in key therapy areas.

The implementation of the job cuts will commence immediately, with affected employees being notified in the coming months in accordance with local labor regulations. Novo Nordisk, headquartered in Bagsvaerd near Copenhagen, currently employs 78,400 individuals.

Following the announcement, shares of Novo Nordisk saw a 1.1% increase in pre-market trading. Doustdar, who assumed the role of CEO in May, succeeded Lars Fruergaard Jorgensen amidst challenges faced by the company, including declining share prices and competition from rival pharmaceutical companies like Eli Lilly.

Novo Nordisk experienced a surge in market value following the successful launch of Wegovy and Ozempic, both of which are based on semaglutide, a key ingredient. At its peak, the company’s market capitalization exceeded Denmark’s annual gross domestic product, establishing it as Europe’s most valuable company.

In conclusion, Novo Nordisk’s decision to reduce its workforce reflects its commitment to adapting to market changes and focusing on innovation in diabetes and obesity treatment. This strategic realignment is aimed at ensuring the company remains competitive and continues to deliver impactful solutions in the healthcare industry.